Weekly News Roundup — RSV Breakthrough Data, Psychedelic Approvals on the Horizon, and Major FDA Policy Shifts

episode

tHEORetically Speaking not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from tHEORetically Speaking

From Data Access to Evidence Usability: Connecting Payer Policy, Real-World Data, and Clinical Context to Close the Evidence Gap 11 min · 13 Jul 2026

All episodes from tHEORetically Speaking →

Report any issue

Source

Recorded20 Feb 2026

Publisherfeeds.buzzsprout.com

Handlerec:16025348

Show notes

This week’s tHEORetically Speaking News Roundup covers new real-world data showing Sanofi’s Beyfortus delivering multi-season protection against RSV hospitalizations, Compass Pathways’ positive Phase 3 results for its psilocybin therapy in treatment-resistant depression, and the FDA’s move toward a single-trial approval standard. We also explore stabilizing telehealth utilization trends and new FDA scrutiny of SSRI and RSV antibody safety. Tune in for this concise recap of these pivotal industry updates!

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.